Muhammad Amanullah | August 17, 2026
The True Post: Teva Canada has announced the recall of specific lots of its Teva-Pregabalin 150 mg capsules in Canada after routine testing identified possible contamination with another medication, sertraline. The company said the affected capsules are being recalled as a precautionary measure.
According to Health Canada, the recall involves two specific lots of Pregabalin 150 mg. Consumers and healthcare professionals have been advised to identify the affected products and return any capsules from those lots to a pharmacy as soon as possible.
Two Lots Affected
The two recalled lots are 100070495 and 100068913. According to Health Canada, the affected products began being sold in Canada in September 2025 and have an expiry date of July 31, 2027.
Teva Canada emphasized that not all Teva-Pregabalin capsules are being recalled. The recall applies only to the two identified lots, making it important for patients to check the lot number printed on their medication packaging.
In a public notice issued Friday, Teva Canada described the recall as a precautionary action after routine quality testing identified a potential cross-contamination issue.
Possible Sertraline Contamination
According to Health Canada, the concern arose after the possible presence of sertraline was identified in the affected Pregabalin capsules.
Sertraline is a different prescription medication used to treat symptoms associated with several mental health conditions. Health authorities have raised particular concerns for people who are sensitive or allergic to sertraline.
People with a sensitivity or allergy to sertraline could experience adverse reactions if exposed to the medication. In severe cases, an allergic reaction can become serious and may include anaphylaxis, a potentially life-threatening condition.
What Should Patients Do?
Health Canada has advised people who have the affected lots to return the capsules to a pharmacy as soon as possible.
However, patients should not stop taking prescription medication on their own. They should speak with their doctor or pharmacist before making changes to their treatment.
This is particularly important because Pregabalin is a prescription medication that is used regularly by patients for various medical conditions. Suddenly stopping treatment or changing the prescribed dosage without medical advice may cause problems for some patients.
Anyone who develops unusual or severe symptoms after taking the affected medication should seek medical attention, particularly if they experience symptoms that could indicate a serious allergic reaction.
What Is Pregabalin Used For?
Pregabalin is a prescription medication used for several medical conditions. According to Canadian health authorities, one of its important uses is the treatment of nerve pain caused by nerve damage.
Nerve pain can differ from ordinary pain and may involve burning, tingling, pins-and-needles sensations or feelings similar to electric shocks. Pregabalin may be prescribed to patients experiencing pain associated with nerve damage.
Sertraline, meanwhile, is a different type of prescription medication. It is used to treat depression and symptoms associated with conditions such as obsessive-compulsive disorder (OCD) and panic disorder.
Health Authorities Take Precautionary Action
The recall by Teva Canada and Health Canada’s warning to consumers highlight the importance of quality control and contamination monitoring during the production of prescription medicines.
The purpose of recalling the affected products is to protect patients from potential risks after the possible contamination was identified.
Since the issue involves only two specific lots, patients are advised not to panic but to check the lot number on their medication packaging.
Anyone whose Pregabalin packaging carries lot number 100070495 or 100068913 should avoid using the affected product and contact a pharmacy for further guidance.
Patients should follow instructions from Health Canada, Teva Canada, their doctor and pharmacist to determine the safest next step and whether an alternative medication is required.
